LETROZOLE 2.5 - Rohm Labs

Letrozole, developed by Novartis and sold as Femara, was approved in 1997 by the FDA as a next-generation treatment for breast cancer in estrogen-sensitive cases. Recognized globally in over 70 countries, it remains one of the most widely used inhibitors today. This non-steroidal medication blocks aromatase, reducing estrogen levels up to 78%, even at low doses. While primarily medical, letrozole has gained popularity among athletes to counteract estrogenic effects, though some use requires careful dosing due to potential side effects like mood changes and cholesterol impacts​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about LETROZOLE 2.5 by Rohm Labs, consult with your doctor or healthcare professional.